Article
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Antimicrobial agents and chemotherapy - 1 Aug 2010
Tojo Yasushi, Koh Yasuhiro, Amano Masayuki, Aoki Manabu, Das Debananda, Kulkarni Sarang, Anderson David D, Ghosh Arun K, Mitsuya Hiroaki
Abstract excerpt
Natural products with macrocyclic structural features often display intriguing biological properties. Molecular design incorporating macrocycles may lead to molecules with unique protein-ligand interactions. We generated novel human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) containing a macrocycle and bis-tetrahydrofuranylurethane. Four such compounds exerted potent activity against HIV-1LAI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.